In Study 19 there were 16 patients treated for 6 years or longer, of whom one was on placebo and had a germline mutation in BRCA1. Of the 15 patients on olaparib for more than 6 years, 8 were originally reported as having BRCA mutations.7 One further patient was found to have somatic mutations in both BRCA1 and BRCA2 on Myriad blood and tumour testing (no Foundation Medicine tumour testing data were available); hence, 9/15 patients are known to have a BRCA mutation (5 with BRCA2, 3 with BRCA1 and 1 with both) in their tumour or blood sample, with 3/9 being a somatic mutation. The gene discussed is BRCA2; the disease is neoplasm.